Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 273 clinical trials
Sentinel Lymph Node Sampling for Patients With Middle-high Risk Endometrial Cancer Confined to the Uterus

Aim To investigate the effect of sentinel lymph node (SLN) sampling on the prognosis of patients with middle-high risk endometrial cancer obviously confined to the uterus before surgery.

  • 0 views
  • 09 Apr, 2022
  • 1 location
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)

deficient (dMMR) advanced or recurrent endometrial carcinoma who have not previously been treated with prior systemic chemotherapy. The primary study hypotheses are that pembrolizumab is superior to

paclitaxel
carboplatin
endometrial carcinoma
carcinoma
pembrolizumab
  • 0 views
  • 22 Oct, 2022
  • 121 locations
  • 238 views
  • 22 Oct, 2022
  • 76 locations
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors

), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in

oxaliplatin
carcinoma
antineoplastic
cancer
gemcitabine
  • 0 views
  • 15 Oct, 2022
  • 41 locations
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial

clear cell adenocarcinoma
step 2
serum pregnancy test
cancer
neutrophil count
  • 198 views
  • 21 Oct, 2022
  • 184 locations
A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors (TROPiCS-03)

The primary objective of this study is to assess the objective response rate (ORR) of sacituzumab govitecan-hziy in adult participants with metastatic solid tumors.

ct scan
carcinoma
growth factor
cancer
measurable disease
  • 24 views
  • 24 Oct, 2022
  • 49 locations
Risk-Reducing Surgeries for Hereditary Ovarian Cancer

Patients of Endometrial Cancer" (NCT03291106, clinicaltrials.gov), we provide risk-reducing surgeries of salpingo-oophorectomy with/without hysterectomy for healthy carriers with mutation genes of

  • 18 views
  • 21 Jan, 2021
  • 1 location
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors

This is a Phase 1/2, open-label, FIH study designed to evaluate the safety, tolerability, PK, PDy, and antineoplastic activity of RLY-4008, a potent and highly selective FGFR2 inhibitor, in patients with unresectable or metastatic CCA and other solid tumors. The study consists of 3 parts: a dose escalation (Part 1), …

solid tumor
advanced solid tumor
growth factor
antineoplastic
cancer chemotherapy
  • 5 views
  • 04 Oct, 2022
  • 41 locations
The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology Study (LETSGO)

This study compares traditional follow-up of gynaecological cancer patients to an alternative follow-up model. In the alternative follow-up model the patients will meet a nurse at every second consultation. The nurse will focus on psychosocial health and educate the patients in the use of a study specific smartphone-application.

cancer
cancer of the ovary
ovarian cancer
carcinoma
  • 20 views
  • 19 Feb, 2022
  • 12 locations
A Phase 1a/1b Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care. The study will last up to …

measurable disease
erlotinib
pembrolizumab
cancer
cetuximab
  • 23 views
  • 25 Oct, 2022
  • 30 locations